在COPD患者中对12周每天一次的定剂量蒂奥托/奥洛达特醇组合的差异反应:TORRACTO研究中的多维反应概况
Rein Posthuma1,2,3, Lowie E G W Vanfleteren4,5, Swetlana Gaffron6
1Department of Research and Development, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, the Netherlands.
概括
在慢性阻塞性肺病 (COPD) 中,对长效支气管扩展剂 (LABD) 的反应各不相同. 这项研究确定了不同的患者群体,这些患者群体表现出与tiotropium/olodaterol (T/O) 对运动耐力和肺功能的不同改善.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 数据科学数据科学数据科学
背景情况:
- 长效支气管扩展剂 (LABD) 是慢性阻塞性肺病 (COPD) 的标准治疗方法,通常可以改善症状和运动能力.
- 个体患者对LABD的反应可能非常可变,需要对多维治疗效应有更深入的了解.
研究的目的:
- 描述COPD患者对提奥/奥洛达 (T/O) 治疗的多维反应.
- 根据他们对T / O的反应,使用自组织地图 (SOM) 识别不同的患者群.
主要方法:
- 对TORRACTO研究的二次分析,这是一项随机,双盲,安慰剂控制的试验.
- 使用自组织图 (SOM) 来对患者 (n=268) 进行分组,基于12周T/O治疗后的运动耐力时间,FEV1,FVC,休息IC和同位素IC (ICiso) 的变化.
主要成果:
- 在第12周,发现了6个不同的群体,具有不同的反应概况.
- 集群1显示所有测量结果 (耐力,FEV1,FVC,ICrest,ICiso) 的显著改善.
- 集群5显示耐力时间 (357s) 显著改善,但与基线相比,FEV1,FVC和IC指标有所下降.
结论:
- 个人对COPD患者T/O的反应是异质的,影响了运动耐力和肺功能.
- 这项研究成功地确定了不同的患者集群,对LABD治疗有明显不同的多维反应.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:20COPD: Pathogenesis and Clinical Features
367
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
367
01:19Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317